Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.
Emre M, Poewe W, De Deyn PP, Barone P, Kulisevsky J, Pourcher E, van Laar T, Storch A, Micheli F, Burn D, Durif F, Pahwa R, Callegari F, Tenenbaum N, Strohmaier C.
Emre M, et al. Among authors: pourcher e.
Clin Neuropharmacol. 2014 Jan-Feb;37(1):9-16. doi: 10.1097/WNF.0000000000000010.
Clin Neuropharmacol. 2014.
PMID: 24434526
Clinical Trial.